Form 4: Xeris Biopharma CEO's RSU Vesting & Tax Withholding

Xeris Biopharma CEO John Patrick Shannon Jr. disposed of 36,918 shares to cover tax obligations related to restricted stock unit vesting.

Summary

• John Patrick Shannon Jr., Chief Executive Officer and Director of Xeris Biopharma Holdings, Inc., reported a disposition of 36,918 shares of common stock.
• The transaction occurred on August 1, 2025, at a price of $5.38 per share.
• These shares were withheld by the company to satisfy income tax and withholding obligations in connection with the net settlement of restricted stock units (RSUs) that vested on the same date.
• Following this reported transaction, the CEO directly beneficially owns 2,657,425 shares.
• The total shares beneficially owned include 7,225 shares that were purchased on June 30, 2025, through the company's 2018 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The filing indicates a routine tax-related disposition of shares following the vesting of restricted stock units for the CEO, which is a positive sign of equity compensation realization. Additionally, the CEO's participation in the Employee Stock Purchase Plan and acquisition of new shares demonstrates continued commitment to the company.

Positives

• The vesting of restricted stock units for the CEO indicates the achievement of performance milestones or tenure, reflecting a positive outcome of the company's equity compensation program.
• The CEO's participation in the Employee Stock Purchase Plan (ESPP) and acquisition of 7,225 shares demonstrates continued investment and alignment with shareholder interests.

Negatives

• No discretionary sale of shares by the CEO was reported; the disposition was solely for tax withholding purposes related to RSU vesting, which is a routine event.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Industry Context

This filing details a routine insider transaction for a biopharmaceutical company, specifically the vesting of restricted stock units and associated tax withholding for its CEO. Such transactions are common across industries for executives receiving equity compensation.

Comparison to Industry Standards

• The disposition of shares for tax withholding upon RSU vesting is a standard practice for executive compensation in publicly traded companies across various sectors, including biopharma.
• The CEO's continued significant beneficial ownership of 2,657,425 shares, including recent ESPP purchases, aligns with typical executive equity retention strategies.

Related Party Transactions

• Disposition of 36,918 shares by CEO John Patrick Shannon Jr. to satisfy tax obligations related to the vesting of restricted stock units.
• Acquisition of 7,225 shares by CEO John Patrick Shannon Jr. through the company's 2018 Employee Stock Purchase Plan.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation structure and confirms continued significant insider ownership, which can be viewed positively.
• Employees: Reflects the company's equity compensation program (RSUs, ESPP) and how it operates for executives.

Key Dates

Recommendation

The filing details a routine insider transaction (tax withholding on RSU vesting) and an ESPP purchase, which are common and generally neutral events. It does not provide new financial performance data or strategic updates that would warrant a change in investment recommendation based solely on this filing. The CEO's continued significant ownership is a positive signal.

Keywords

Xeris Biopharma, XERS, insider transaction, Form 4, CEO, restricted stock units, RSU vesting, tax withholding, employee stock purchase plan, equity compensation